Laurus Labs share price hit a new high of ₹2,137, surging 4% on Tuesday's trading session in an otherwise tepid market. According to reports from Business Standard, the stock has now gained 8% over the past two trading days, significantly outperforming the broader market. At 02:32 PM, the stock was quoted 3.6% higher at ₹2,133.15, compared to a 0.44% decline in the BSE Sensex. The average trading volume at the counter jumped 1.5 times with a combined 3.65 million shares changing hands on the NSE and BSE.
Foreign Portfolio Investors (FPIs) have increased their stake in Laurus Labs for the second consecutive quarter, according to shareholding data reported by Business Standard. FPIs increased their stake to 30.8% in the September 2026 quarter (Q2FY27) from 28% at the end of June 2026 quarter. This compares to 25.8% held at the end of March 2026 quarter. Meanwhile, Domestic Institutional Investors (DIIs) holding in Laurus Labs declined to 11.9% in Q2FY27 from 13.7% in Q1FY27 and 14% in Q4FY26. The public shareholding (excluding FPIs and DIIs) in Laurus Labs declined for the fourth straight quarter, reducing their holding to 29.9% in Q2FY27 from 30.8% in Q1FY27.
As reported by Business Standard, Laurus is a research-led pharmaceuticals and biotech company undergoing a super capex cycle. The company has already invested ₹4,300 crore in business with an ongoing capex of more than ₹3,000 crore. Analysts at Nuvama Institutional Equities forecast that Contract Development and Manufacturing Organisation (CDMO) revenue shall grow 3.4 times to ₹7,160 crore by FY29E, with CDMO contributing more than 50% by FY29E. This expansion is expected to enhance earnings before interest, tax, depreciation and amortization (EBITDA) margin profile to near 35%.
According to Nuvama Institutional Equities, the brokerage firm initiated coverage on Laurus Labs in October 2026 with a 'Buy' rating and target price of ₹2,520 per share. The analysts forecast return on equity (RoE) to improve to 23.3% by FY29E (FY26: 16%). As reported by Business Standard, the DuPont breakdown shows this improvement is sustainable as it emanates from margins. The tightly guarded peptide facility is expected to open soon, yielding ₹1,000 crore - ₹1,600 crore in revenue opportunities at a 35% margin. As the capex cycle peaks, free cash flow should improve sharply after FY27E.
